This question is specifically asked within the Project called "Treatment of Melanoma Brain Metastases."
Because neurological tissues as well as many forms of skin malignancies will tend to express at least some significant CB1 and CB2 receptors, perhaps using moderate dosing of a safe agonist like Delta 9-THC may be useful? And consider including evaluation of equivalent to 100-300 mg or oral CBD for humans as well as this is becoming very common among patients.
I work with both brain cancer patients (mostly Glioblastoma) and many breast cancer patients and they had already chosen to integrate cannabis extracts into their therapies. Because CBD and THC cross the BBB, and does not appear toxic to healthy normal cells, it may be reasonable to consider exploring this with research. I do have one interesting patient who reported using these compounds to treat her ER-PR-HER2+ brain metastases with tremendous success in only 3 months. The Herceptin and Perjeta she was on are too large to cross the BBB, so the situation is dire for her otherwise. Best wishes and thank you for your project!
Kristin
I am not sure if you are asking about THC and TBI or TBC and cancer. If the latter, we do not study cancer and it would be difficult at this stage of my career to re-invent myself as cancer researcher. THC and TBI would be of interest (as would THC and PTSD), but we lack the funding resources to pursue that. There are also regulatory issues we would need to address.
Thanks for the thoughts though.
regards
Tony Reiner
Thank you Tony!
Sorry for any confusion. This question was asked in the Project called "Treatment of Melanoma Brain Metastases" ~~ but now I realize that it appears as a question with that Project just mentioned subtly. I will modify my question to make it more clear.
One thing I have been a bit puzzled by is that dronabinol, a Schedule III drug, is not used more in research as a surrogate for the Schedule I THC? I am sure there are good reasons why, but I have still wondered. I know it is more psychoactive than plant extracts as it is a single agent without all of the other constituents normally present which buffer that side effect, but if we are discussing pre-clinical research on reducing existing brain mets in a lab animal, it may work very well, depending on tumor characteristics.
Thank you again ~~
Regards,
Kristin